![](https://news.europawire.eu/wp-content/uploads/2024/01/e38ad046325c6e2c010e6533ea69f735-144x144.jpg)
(IN BRIEF) Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds, currently under Phase II evaluation for the second-line … Read the full press release